2015
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetateMetastatic CRPCProstate cancerPhase III trialsBetter patient selectionHigh-level evidenceRisk of hypertensionDrug resistance patternsCurrent clinical challengesIntratumoral androgensOverall tolerabilityIII trialsPatient selectionClinical efficacySafety profileDevelopment of resistanceTreatment modalitiesDisease progressionTargeted therapyAndrogen sourceClinical challengeAndrogen signalingCYP 17
2014
Reply
Ha Y, Kim I. Reply. Urology 2014, 84: 372. PMID: 24925832, DOI: 10.1016/j.urology.2014.02.040.Peer-Reviewed Original Research
2013
Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance
Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.Peer-Reviewed Original ResearchConceptsGleason score 3Prostate cancerRadical prostatectomyActive surveillanceScore 3Positive coresIncidence of upstagingPrediction of upgradingPSA cutoff levelPreoperative PSA levelUpstaging ratePSA levelsCancer involvementClinical stageNeedle biopsyUpstagingPatientsCutoff levelBiopsyMarginal associationIncidenceOverall rateCancerSurveillanceProstatectomy